Reducing androgen levels or blocking androgen receptors (AR) can inhibit the progression of prostate cancer, making androgen deprivation therapy (ADT) a first-line treatment to prevent the progression and metastasis of prostate cancer [3]. This evidence concerns the gene AR and prostate carcinoma.